List of works - Paola Bordi

2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC.

scientific article published on 15 April 2016

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity.

scientific article

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).

scientific article published on 14 December 2016

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

scientific article

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

scientific article

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.

scientific article published on 26 March 2018

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.

scientific article published on 20 January 2016

Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.

scientific article

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

scientific article published on 2 April 2013

Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.

scientific article published on March 2015

Enteral administration of TKIs: report of a response to ceritinib in an ALK-positive NSCLC patient and literature review

scientific article published on 12 February 2018

Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients

scientific article published on 12 October 2014

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

scientific article published on 30 May 2016

Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.

scientific article published on 28 October 2017

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report.

scientific article

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

scientific article published on 16 June 2017

Narrative literature and cancer: improving the doctor-patient relationship

scientific article published on November 1, 2012

Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report

scientific article published in January 2014

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

scientific article published on 15 September 2017

Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non-Small-cell Lung Cancer: A Multicenter Italian Survey.

scientific article published on 22 November 2016

Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients

scientific article

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

scientific article

Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors

scientific article published on August 2015

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

scientific article

List of works by Paola Bordi

2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC.

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity.

Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs).

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA.

Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment.

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin

Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.

Enteral administration of TKIs: report of a response to ceritinib in an ALK-positive NSCLC patient and literature review

Gene mutations in small-cell lung cancer (SCLC): results of a panel of 6 genes in a cohort of Italian patients

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

Lung Toxicity in Non-Small-Cell Lung Cancer Patients Exposed to ALK Inhibitors: Report of a Peculiar Case and Systematic Review of the Literature.

Metabolic complete response with vinflunine as second-line therapy in a kidney-transplanted patient with advanced urothelial carcinoma: a case report.

Molecular profiling in Italian patients with advanced non-small-cell lung cancer: An observational prospective study.

Narrative literature and cancer: improving the doctor-patient relationship

Overcoming T790M-driven acquired resistance to EGFR-TKIs in NSCLC with afatinib: a case report

Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment.

Patients' Attitudes and Physicians' Perceptions Toward Maintenance Therapy for Advanced Non-Small-cell Lung Cancer: A Multicenter Italian Survey.

Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

Radiotherapy of non-small-cell lung cancer in the era of EGFR gene mutations and EGF receptor tyrosine kinase inhibitors

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.